Role of JAK/STAT3 Signaling in Functional Stimulation of Mesenchymal Progenitor Cells by Fibroblast Growth Factor


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

JAK/STAT signaling pathway was examined during functional stimulation of mesenchymal progenitor cells with fibroblast growth factor. The differences were observed in the realizations of the proliferation-differentiation potential of CFU-fibroblasts under blockade of JAKs or during selective inactivation of STAT3. The study revealed stimulating influences of JAKs and STAT3 on mitotic activity of progenitor cells and individual roles of these proteins in the control of their maturation. Blockade of JAKs diminished the level of fibroblast colony formation and the score of actively proliferating CFU-fibroblasts at the background increase of the differentiation rate of progenitor cells. In contrast, STAT3 inhibitor resulted in a coordinated decrease of all examined parameters.

Sobre autores

G. Zyuz’kov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; National Research Tomsk State University

Autor responsável pela correspondência
Email: zgn@pharmso.ru
Rússia, Tomsk; Tomsk

E. Udut

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

L. Miroshnichenko

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

T. Polyakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

E. Simanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

L. Stavrova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

G. Prosekin

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

M. Minakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

E. Borodulina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

I. Mareev

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

R. Gurto

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

V. Zhdanov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: zgn@pharmso.ru
Rússia, Tomsk

V. Udut

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; National Research Tomsk State University

Email: zgn@pharmso.ru
Rússia, Tomsk; Tomsk


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies